Candel Therapeutics, Inc. (CADL) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
8.52
↑+139% vs avg
5yr avg: 3.56
30Y Low1.1·High5.8
ROE
↑
N/A
—
5yr avg: -119.2%
30Y Low-178%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CADL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Candel Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $459M | $299M | $275M | $43M | $52M | $224M | — | — |
| Enterprise Value | $342M | $181M | $186M | $30M | $4M | $142M | — | — |
| P/E Ratio → | -11.60 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 412.75 | 1794.84 | — | — |
| P/B Ratio | 8.52 | 5.76 | 4.15 | 3.34 | 1.08 | 3.50 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CADL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 34.69 | 1138.18 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
CADL Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | -11575.2% | 100.0% | -5185.6% |
| Operating Margin | — | — | — | — | -27777.6% | -20580.8% | -11048.0% | -7229.6% |
| Net Profit Margin | — | — | — | — | -15035.2% | -28899.2% | -14144.0% | -6592.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -139.6% | -125.5% | -33.6% | -178.1% | — | — |
| ROA | — | — | -74.5% | -63.4% | -22.4% | -56.7% | -42.0% | -18.0% |
| ROIC | — | — | — | -10470.3% | — | — | — | — |
| ROCE | -52.0% | -52.0% | -69.3% | -76.8% | -44.3% | -43.8% | -35.4% | -20.3% |
CADL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $120M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.20 | 1.79 | 0.48 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.27 | -1.34 | -0.99 | -0.99 | -1.28 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -15.97 | -74.69 | -20.33 | -485.40 | — | — |
Net cash position: cash ($120M) exceeds total debt ($2M)
CADL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Candel Therapeutics, Inc.'s current ratio of 13.31x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.59x to 13.31x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.31 | 13.31 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 | 32.06 |
| Quick Ratio | 13.31 | 13.31 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 | 32.06 |
| Cash Ratio | 13.31 | 13.31 | 2.74 | 2.50 | 12.48 | 15.41 | 7.44 | 31.96 |
| Asset Turnover | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
CADL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Candel Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $53M | $32M | $29M | $29M | $29M | $19M | $19M |
Peer Comparison
Compare CADL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CADLYou | $459M | -11.6 | — | — | — | — | — | — | — |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 IMCR | $2B | -55.8 | — | — | 97.9% | -11.3% | -7.1% | -17.2% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 FATE | $276M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NKTR | $2B | -8.4 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ADCT | $445M | -3.1 | — | — | 90.6% | -133.2% | — | — | — |
 CLDX | $2B | -8.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 NVAX | $2B | 4.0 | 2.8 | — | 93.7% | 50.1% | — | — | 0.4 |
 CRSP | $5B | -8.5 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See CADL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CADL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CADL vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonCADL — Frequently Asked Questions
Quick answers to the most common questions about buying CADL stock.
What is Candel Therapeutics, Inc.'s P/E ratio?
Candel Therapeutics, Inc.'s current P/E ratio is -11.6x. This places it at the 50th percentile of its historical range.
Is CADL stock overvalued?
Based on historical data, Candel Therapeutics, Inc. is trading at a P/E of -11.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.